LWLi Wei

Li Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Li Wei has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Jian Liu

    Department of Thoracic Surgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou 450003, Henan, China

    4 shared publications
  • Tian Xia

    Department of Thoracic Surgery, Zhengzhou University People's Hospital, Zhengzhou 450000, Henan, China

    4 shared publications
  • Xiangbo Jia

    Department of Thoracic Surgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou 450003, China

    3 shared publications
  • Jianjun Wang

    Henan Univ, Sch Clin Med, Zhengzhou Univ, Henan Prov Peoples Hosp,Peoples Hosp,Dept Thorac, Zhengzhou, Peoples R China

    2 shared publications
  • Lei Xu

    Department of Thoracic Surgery, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, China

    2 shared publications
  • Li Zhu

    Zhengzhou Univ Peoples Hosp, Henan Prov Peoples Hosp, Dept Thorac Surg, Zhengzhou, Peoples R China

    2 shared publications

Latest Publications

  • Open Access

    HMGA1 drives EMT in obliterative bronchiolitis through epigenetic regulation of chromatin accessibility in pulmonary epithelial cells

    by Tian Xia, Zhaoyao Hou, Sihua Wang, Jingyao Sun, Hui Yang, Peng Miao, Chang Liu, Wantong Zheng, Li Wei

    Background Post-transplant obliterative bronchiolitis (OB) is a major cause of lung graft dysfunction and failure, with the epithelial-mesenchymal transition (EMT) process playing a pivotal role in driving extracellular matrix (ECM) deposition and fibrosis. Methods A mouse heterotopic tracheal allograft model was established to replicate the clinical manifestations of post-transplant OB. Histopathological alterations of tracheal grafts were assessed using Hematoxylin and Eosin (HE) staining. Gene expression was quantified through enzyme-linked immunosorbent assay (ELISA), immunofluorescence (IF), immunohistochemistry (IHC), reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and Western blot assays. Differentially expressed genes (DEGs) in heterotopic tracheal grafts were identified by RNA sequencing (RNA-Seq). Chromatin accessibility was evaluated using assay for transposase-accessible chromatin with sequencing (ATAC-Seq). Results Histological analysis revealed progressive luminal occlusion (7-14 days), with significant inflammatory infiltration at day 7 and ECM deposition at day 14. Elevated IL-1β/IL-6 levels and reduced IL-10 confirmed immune activation. High mobility group at-hook 1 (HMGA1) was upregulated in allografts and mediated TGF-β1-driven EMT in vitro. Integration of ATAC-seq and RT-qPCR in pulmonary epithelial cells demonstrated that HMGA1 orchestrates extensive chromatin remodeling during OB pathogenesis. HMGA1 directly enhanced chromatin accessibility at EMT-promoting loci, including specificity protein 1 (SP1), dedicator of cytokinesis 4 (DOCK4), serum response factor (SRF), and anillin (ANLN). Epigenetic reprogramming of these regulatory regions induced TGF-β1-mediated EMT. Conclusions HMGA1 promotes EMT in OB by facilitating chromatin accessibility at EMT-associated loci, highlighting its potential as a therapeutic target for post-transplant intervention.


  • Open Access

    A case of giant esophageal leiomyoma in the upper and middle segments

    by Peng Miao, Zhijun Han, Li Wei

  • Open Access

    Development of an Anoikis-Related Gene Signature for Lung Squamous Cell Carcinomato Predict Prognosis, Immune Landscape, and Immunotherapy Response

    by Jian Liu, Hui Zheng, Li Wei

    Background. Anoikis, a form of programed cell death, plays a pivotal role in the invasion and metastasis of various tumors, including lung squamous cell carcinoma (LUSC). This study aims to construct a prognostic model for LUSC, leveraging anoikis-related genes (ARGs). Methods. A total of 357 ARGs were extracted from the GeneCards database and Harmonizome portals. Subsequently, ARGs influencing LUSC patients prognosis were identified using univariate Cox regression analysis. Unsupervised clustering analysis was carried out utilizing the consensusplus R package, and LASSO regression was deployed to craft a risk regression model. The IBOR R package quantified the immune cell infiltration abundance. Moreover, the maftools R package, paired with the GISTIC online tool, facilitated the assessment of gene copy number variations. Experimental validation was conducted through RT-PCR, evaluating the differential expression of eight pivotal genes, and cellular functional assays discerned the influences of the CHEK2 and SDCBP genes on LUSC cells migratory and invasive capabilities. Results. Fifteen survival-associated ARGs delineated three molecular subtypes within the TCGA-LUSC cohort. An eight ARG-based risk prognostic model was constructed, delineating significant survival disparities between high and low-risk groups. Notably, the low-risk group manifested a diminished propensity for immune therapy evasion and gene mutations. A comprehensive nomogram, incorporating risk scores and clinical attributes, was fashioned, exemplifying remarkable predictive acumen. Cellular functional assays substantiated that the modulation of CHEK2 and SDCBP expressions conspicuously influenced the migratory and invasive propensities of LUSC cells. Conclusions. This rigorous study unveils novel anoikis-related biomarkers integral to LUSC prognostication. The meticulously constructed risk prognostic model, underscored by these biomarkers, augurs a potent predictive tool for enhancing the LUSC patient prognosis and therapeutic strategies.


  • Construction and validation of an efferocytosis-related prognostic signature in lung adenocarcinoma

    by Jian Liu, Li Wei

    Background Accumulating evidence highlights the potential significance of efferocytosis in tumor progression. This study is directed towards the construction of a prognostic risk model for lung adenocarcinoma (LUAD), grounded on efferocytosis-related genes (ERGs). Methods Employing LASSO-COX regression analysis, a risk-prognostic model was formulated, centered on seven ERGs. Concurrently, a nomogram was established that incorporated patient clinical features and risk scores. The predictive accuracy of the risk model and the nomogram was substantiated via external validation sets. The landscapes of immune infiltration and genetic mutation were evaluated for high- and low-risk groups, with the expression of seven key genes validated through RT-PCR. Results Our findings reveal that the high-risk group displayed considerably inferior survival outcomes in comparison to the low-risk group. A diminished abundance of immune cell infiltrates and a higher prevalence of gene mutations characterized the high-risk group. Genes with high expression were markedly enriched in pathways related to cell proliferation. The superior predictive performance of the risk model and nomogram was adequately substantiated by the external validation sets (GSE31210, GSE30219, and GSE50081). In addition, we discerned several potential therapeutic drugs demonstrating different sensitivities across patient risk groups. The differential expression of seven central genes was confirmed in A549, H1299, and BEAS-2B cell lines. Conclusion The constructed risk model and nomogram display high accuracy in predicting the survival and immune landscape of LUAD patients, thus providing invaluable prognostic tools in clinical scenarios.


  • Open Access

    Development of an anoikis-related gene signature for lung squamous cell carcinoma to predict prognosis, immune landscape, and immunotherapy response

    by Jian Liu, Li Wei

    Background Lung squamous cell carcinoma (LUSC) is a highly invasive malignancy associated with a poor prognosis. Anoikis plays a crucial role in the malignant progression of various cancers. However, studies focusing on the role of anoikis in LUSC are needed. Methods A total of 357 anoikis-related genes (ARGs) were obtained from the GeneCards database and Harmonizome portals. Univariate Cox regression was used to identify prognostic ARGs for patients with LUSC, and the R package ConsensusClusterPlus was used to determine the subtypes. Lasso regression was used to build a prognostic risk model called the ARG score. Functional enrichment analysis was used to investigate the potential biological function of the ARGs. The ESTIMATE, ssGSEA, and CIBERSOT algorithms were used to evaluate the pattern of immune infiltration of patients with different LUSC subtypes and risk groups. The R package timeROC, survival, and survminer were used to test the accuracy of the prognostic model and to construct a nomogram. RT-PCR was used to detect differential expression of the 9 hub genes in LUSC and normal lung epithelial cells. Finally, OncoPredict was used to identify drugs with therapeutic value for patients in the high and low-risk groups. Results A total of 138 differentially expressed ARGs were selected, among which 15 survival-related ARGs were identified, and 3 subtypes (A, B, and C) with significant differences in the immune infiltration and survival outcomes were determined. Nine prognostic ARGs were identified to construct prognostic models, and the predictive capacity was verified in the GSE73403 and GSE30219 datasets. Patients with a high-risk score had worse outcome, and were associated with Tregs, resting memory CD4 + T cells, neutrophils, immune escape phenotypes, inflammatory response, and epithelial–mesenchymal transition. A nomogram with excellent clinical diagnostic accuracy was established for LUSC patients. The 9 hub genes had lower expression in LUSC cell lines, except for CHEK2, FADD, and SPINK1. Finally, we identified several drugs for patients in different risk groups. Conclusions ARGs play a key role in LUSC, and the ARG score devised in this study may be a valuable tool for determining clinical prognosis and the immunotherapy response in patients with LUSC.


  • Open Access

    Association between the frequency of tooth brushing and esophageal carcinoma risk: an update systematic review and meta-analysis

    by Li Zhu, Jianjun Wang, Quan Zhang, Tian Xia, Shuai Hu, Wenjian Yao, Li Wei

    Background: Lower frequency of tooth brushing was thought to be associated with esophageal carcinoma (EC). However, some researchers suggested that this association did not exist or had not yet reached statistical significance. The purpose of this study was to calculate a more precise estimation of the relationship between the frequency of tooth brushing and the risk of EC by combining the results between different studies using the meta-analysis. Methods: We searched the PubMed, Embase, Web of Science, and Scopus electronic databases up to July 2021. According to PECO approach (Population, Exposure, Comparator and Outcomes), we assessed the association between tooth brushing frequency and EC risk which reported the adjusted risk ratios (adjRR), hazard ratios (adjHR), or odds ratios (adjOR) with 95% confidence interval (CI). The random effects model was used to quantitatively evaluate the combined results. Two researchers independently evaluated the risk bias of the included studies using the Newcastle-Ottawa Scale (NOS). The robustness of results was evaluated by subgroup analysis, sensitivity analysis, and publication bias. Results: In total, we identified 13 articles with 14 case-control studies which included 16,773 participants and 5,673 patients. Pooled results showed the lowest frequency of brushing was significantly associated with an increased risk of EC in comparison to the highest (adjOR: 2.00, 95% CI: 1.61–2.48). There was moderate heterogeneity among included studies (P=0.001, I2=61.4%). The original studies included in this meta-analysis were all case-control studies. Study quality was all moderate or above based on NOS score ranges of 6 stars or more. Conclusions: Available evidence suggests a low frequency of tooth brushing may be an important risk factor for EC. However, higher quality studies should continue to be conducted to investigate the optimal threshold of brushing frequency for the prevention of EC.


  • Open Access

    Epigenetic Regulator KDM4D Restricts Tumorigenesis via Modulating SYVN1/HMGB1 Ubiquitination Axis in Esophageal Squamous Cell Carcinoma

    by Wenjian Yao, Jianjun Wang, Li Zhu, Xiangbo Jia, Lei Xu, Xia Tian, Shuai Hu, Sen Wu, Li Wei

    Background: Increasing researches have been reported that epigenetic alterations play critical roles in ESCC development. However, the role of the histone demethylase KDM4D in ESCC tumorigenesis is poorly investigated. This study aims to discover the underlying mechanisms between KDM4D and ESCC progression.Methods: CCK-8 assays, clone formation assay and soft-agar assays were performed to assess cell proliferation. Transwell assay was utilized to assess cell migration efficiency, while sphere formation assay was used to evaluate the cell self-renewal ability. Bioinformatic analysis was conducted to identify prognostic factors and predict the potential E3 ubiquitin ligases. In vitro ubiquitination assay was conducted to confirm the regulations between SYVN1 and HMGB1. The mRNA levels or protein levels of genes were detected by real-time PCR and western blot analysis. In vivo tumor xenograft models were used to determine whether the HMGB1 inhibition affected the malignant features of ESCC cells.Result: Epigenome screening and low-throughput validations highlighted that KDM4D is a tumor suppressor in ESCC. KDM4D expressed lowly in tumors that predicts poor prognosis. KDM4D deficiency significantly enhanced tumor growth, migration and stemness. Mechanistically, KDM4D transcriptionally activates SYVN1 expressions via H3K9me3 demethylation at the promoter region, thereby triggering the ubiquitin-dependent degradation of HMGB1. Low KDM4D depended on accumulated HMGB1 to drive ESCC progression and aggressiveness. Targeting HMGB1 (Glycyrrhizin) could remarkably suppress ESCC tumor growth in vitro and in vivo, especially in KDM4D-deficient cells.Conclusions: We systematically identified KDM4D/SYVN1/HMGB1 axis in ESCC progression, proving novel biomarkers and potential therapeutic targets.